Bioregnum channel feed – Endpoints News

Bioregnum channel feed

FDA OKs a trial for a new Covid-19 therapy after an unusual publicity campaign touts its potential — with help from Rudy Giuliani

6 years ago

No, Mr. President, you can’t just order up outbreak meds with the snap of your fingers

6 years ago

The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019

6 years ago

Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects

6 years ago

Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it

6 years ago

The power of precedent: How a one-off decision by Janet Woodcock established an unintended fast pathway at the FDA — what will follow?

6 years ago

The FDA unveils a new regulatory framework to speed along gene therapies, rewarding the leading players

6 years ago

The FDA has devalued the gold standard on R&D. And that threatens everyone in drug development

6 years ago

Bernie Sanders goes after BioMarin's shot at a record drug price, threatening to break the patent

6 years ago

Oh Canada! There is no Santa Claus to the north giving out cheap drugs to US patients

6 years ago

There’s one endpoint that the booming biopharma industry has failed at miserably: financial toxicity

6 years ago

Biogen's Al Sandrock says the FDA needs to approve their controversial Alzheimer's drug — now

6 years ago

Stephen Hahn gets through Senate’s softball job interview — but mostly plays dodgeball on the issues facing the FDA

6 years ago

Elizabeth Warren proposes using compulsory licensing, antitrust actions to break biopharma’s control of drug pricing — and here are the blockbusters she’s targeting first

6 years ago

From $0 to $12B in an instant. Here's why biopharma loves risky Alzheimer's studies

6 years ago

‘There are moments’: Sanofi’s new CEO is thinking through the R&D strategy — and oncology will be key

6 years ago

Another big biopharma merger runs into another snag at the FTC. What now?

6 years ago

#UKBIO19: Join GSK’s Hal Barron and a group of top biotech execs for our 2nd annual biotech summit in London

6 years ago

Investors lost big as Alzheimer’s R&D went over the cliff in 2019. Will they ever come back?

6 years ago

Once again Novartis’ cardio team looks to beat the odds using sketchy data and a familiar argument

6 years ago

Remember that post-marketing trial? New study confirms many drugmakers don’t do them — half drag their feet

6 years ago

The FDA’s very public slap of Novartis’ red face is a warning to the entire industry — don’t downplay it

6 years ago

Do you want to see what winning big in the R&D race looks like in the Big Pharma league?

6 years ago

What makes Hal Barron tick? Look at the people he’s teaming up with at GSK

6 years ago

First page Previous page 7 8 91011 12 13 Next page Last page